Skip to content

Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance

Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued

Calculus invests in Raindog Films

Raindog is the production company founded by Oscar®-winning actor Colin Firth and former Sony Music CEO Ged Doherty, now joined by writer/producer Trish D Chetty Building on the platform of a robust award-winning film track-record, Raindog will expand into TV drama, music content and documentaries The UK Creative Content EIS Fund has invested in Raindog … Continued

Branston Pickle and Sarson’s Vinegar owner Mizkan selects Wonderhood to creative account

Food giant Mizkan has announced that Wonderhood Studios will take over its creative account from Mcgarrybowen, focusing on advertising for the firm’s food portfolio. This includes Branston Pickle which is coming up to its 100-year anniversary. Vanni Cataldi, Mizkan’s head of marketing, said: “I was really impressed by Alex [Best, Wonderhood Studios’ chief operating officer] and … Continued

Wazoku makes two senior hires

Idea management scaleup Wazoku has made two new senior hires, as the company readies itself for further growth in 2020. Kathryn Layland joins as Chief Revenue Officer (CRO) based in Wazoku’s London HQ, while Alex Butucea arrives as Wazoku’s new Director of Software Engineering, in the company’s Bristol office.  Layland has held senior global revenue positions with several AdTech solution providers and has experience of growing and scaling SaaS … Continued

Weedingtech featured on BBC News Online

BBC news reported on Foamstream, the herbicide-free weed control product of Weedingtech, and its use across council parks and other public spaces. Leo de Montaignac, Chief Executive of Weedingtech, was quoted in the article: “I think that we’re only just seeing the very start of this market, and I think that over the next couple … Continued

Momentum growing with Scancell antibody platform as third agreement signed

Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell’s proprietary AvidiMab™ technology. This is the … Continued

A year in the life of Calculus – 2019

Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. 03.01.20 It was the year of Brexit (again), another bruising general election, and trauma in the retail fund industry with the demise of Woodford and the … Continued

Oxford BioTherapeutics Initiates U.S. Phase I Clinical Trial

Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued

Calculus begins the year with a successful exit for Once Upon a Time

Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus Capital has sold their investment in London-based marketing agency Once Upon a Time (OUAT) in a deal which delivered a 1.8x share price return on investment not … Continued